hope research center

nav

science-product-detail

https://doi.org/10.1142/S2661318220500188

SARS-CoV-2 and Assisted Reproductive Technology Practice An Asia Pacific Initiative on Reproduction (ASPIRE) Position Paper

Budi Wiweko 1, Tuong M. Ho 2, Rong Li 3, Tin-Chiu Li 4, Chii-Ruey Tzeng 5, Gab Kovacs 6, Atsushi Tanaka 7, Jung Ryeol Lee 8, Hrishikesh Pai 9, Haroon Latif Khan 10, on behalf of the Asia Pacific Initiative on Reproduction (ASPIRE)

1 Department Obstetric Gynecology Faculty of Medicine Universitas Indonesia — Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
2 IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam
3 Department of OB & GYN, Reproductive Medical Center, Peking University Third Hospital, Beijing, China
4 Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong
5 Taipei Fertility Center, Taipei, Taiwan
6 Monash University, Melbourne, Australia
7 Saint Mother Hospital & Juntendo University, Japan
8 Department Obstetric Gynecology, Seoul National University Bundang Hospital,
Seoul National University College of Medicine, Korea
9 Medical Director, Lilavati Hospital IVF and Bloom IVF Group India
10 Lahore Institute of Fertility and Endocrinology, Hameed Latif Hospital, Lahore, Pakistan

Abstract

Background: Asia Pacific Initiative on Reproduction (ASPIRE) aims to improve knowledge and awareness of Assisted Reproductive Technology (ART) and infertility-related services, with the aim of improving the quality of patient care.
Methods: A survey was developed and responded by a group of 10 ASPIRE board members to gather in-depth information about current practices, recommendations, and perceptions about SARS-CoV-2 and ART. The collected data were summarized and individual responses pooled among questions requiring voting. The overall rates were computed by response category. The group discussed the summary evidence, until a consensus was reached concerning a series of recommendation on how to make decisions concerning ART service provision during the current (and any future) pandemic. A two-tier recommendation was developed based on agreement rate and implementation priority. Tier 1 comprises recommendations in which the rate of “absolutely agree” responses were ≥60%, whereas tier 2 refers to recommendations in which the rate of “absolutely agree” plus “agree” was >60%, but the rate of “absolutely agree” was ≤50%.
Results: The survey was responded by all participants between July 24 and July 30, 2020. Nine tier 1 and five tier 2 recommendations are provided concerning prevention, testing, personal protective equipment, informed consent, and quality management. The former indicates the situations in which most individuals should receive the intervention/procedure, whereas the latter relates to those that may be suitable for individual clinics and patients.
Conclusions: This document provides the ASPIRE viewpoint on better managing infertile patients seeking ART during the COVID-19 pandemic. This expert opinion guide aims to help both competent authorities and healthcare providers to deliver quality and safe ART.
 

KEYWORDS:

SARS-CoV-2; COVID-19; Assisted Reproductive Technology; Intrauterine Insemination; Infertility; In Vitro Fertilization; Intracytoplasmic Sperm Injection; Guideline; Expert Opinion

Download

Similar articles